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Abstract
The clinical efficacy of the allergen‐specific immunotherapy (AIT) has been well‐docu‐
mented using inhalant or hymenoptera‐derived allergens in atopic patients with cor‐
responding specific IgE antibodies. AIT is considered as the unique treatment that 
is capable of modifying the natural course of the allergic disease because it induces a 
variety of immunological mechanisms, with emphasis in the production of blocking IgG 
antibodies by IL‐10‐stimulated B cells due to the generation of Treg, Breg, or even Th2 
cells. Thus, the measurement of specific IgG subclasses, particularly IgG4, to the crude 
extract or more importantly to allergen components, might be a useful and potential tool 
to follow‐up objectively the patients undergoing AIT in addition to clinical parameters. 
In this chapter, the authors have emphasized a very sensitive and highly specific reverse 
ELISA, developed by them, to measure IgG subclasses directed to clinically relevant 
natural allergens that are undoubtedly better when compared to those obtained with 
recombinant counterparts. Such a technique may produce more authentic results taking 
into account the IgG subclass binding capacity to a particular allergen and might be a 
valuable and alternative method for monitoring activation of tolerance‐inducing mecha‐
nisms in patients under AIT.
Keywords: allergen‐specific immunotherapy, immunotherapy follow‐up, blocking 
antibody, IgE, IgG4
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1. Introduction
Allergen‐specific immunotherapy (AIT) is indicated for atopic patients with IgE‐mediated aller‐
gic diseases, particularly in allergic rhinitis, mild or moderate asthma and hymenoptera sting 
allergy. AIT is an effective treatment that aims to induce changes in immune response against 
specific allergen components derived from causal agents instead of the exteriorized symptoms, 
helping for modifying the natural course of the allergic disease and improving the patients’ 
quality of life by the reduction of symptoms and medication use when naturally exposed to 
sensitized allergens. It involves a build‐up phase that consists of the administration of gradu‐
ally increasing levels of specific allergens until an effective dose that enables the reduction of 
the severity of the disease is reached, even in the presence of the natural allergen exposure [1].
On the one hand, the classical respiratory allergic disease is mediated by IgE antibodies to 
indoor or outdoor inhalant allergens through the development of Th2 cells that produce a 
well‐known cytokine profile, including IL‐4 and IL‐13 [2]. These cytokines are crucial to cause 
antibody class switch on B cells to induce the synthesis of IgE antibodies, which in turn bind 
to mast cells and basophils that possess Fc epsilon receptor (FcεR types I or II) on their mem‐
branes, inducing the sensitization phase. In subsequent contacts, allergens containing genu‐
ine‐ or cross‐reactive epitopes capable to cross‐link to IgE bound to target cells can activate 
these cells, with consequent release of preformed and newly formed vasoactive mediators. 
The preformed mediators (histamine) are responsible for early phase symptoms and newly 
formed those (leukotrienes and cytokines) for inducing a late‐phase response, characterizing 
the type I hypersensitivity reaction [3].
On the other hand, the administration of allergens by AIT has been proved to cause early aller‐
gen‐specific mast cell desensitization, likely as a consequence of the development of regulatory 
T cells (Tr1 cells) that particularly produce IL‐10, which induces antibody class switch on B cells 
to produce IgG4 antibody subclass. An alternative way to produce other subclasses of IgG can 
be achieved due to the fact that AIT can provoke immune deviation from Th2 in favor of Th1 
responses that culminate in the production of IFN‐γ, which induces B cells to produce IgG1 sub‐
class [4]. In the initial phase of AIT the immunological response involves the production of IgG1 
antibodies whereas IgG4 is the dominant subclass in prolonged AIT. Therefore, IgG antibodies 
induced by AIT may act as blocking antibodies, reflecting in the reduction of mast cell activa‐
tion and degranulation as well as competing with IgE antibodies for allergen binding, blocking 
IgE‐dependent mast cell activation and inhibiting IgE‐facilitated allergen presentation [1].
Currently, there is no routine laboratorial test for the detection of allergen‐specific IgG anti‐
bodies, particularly IgG1 and IgG4 subclasses. Physicians, who assist patients with respira‐
tory allergy that have been submitted to AIT, are following the treatment of such patients 
only by subjective clinical parameters. The possibility of following such patients under 
AIT by laboratorial evaluation of allergen‐specific IgG1 and/or IgG4 levels has stimulated 
researchers to develop objective methods for quantifying allergen‐specific IgG antibodies.
The detection of IgG antibodies, particularly IgG1 and IgG4 subclasses, against specific aller‐
genic components, such as the major allergens of Dermatophagoides pteronyssinus (Der p 1 and 
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Der p 2) would indicate the development of a physiological response, i.e., a defense response 
against dust mite allergens [5]. Production of specific IgG4 antibodies to relevant allergenic 
components has been associated with the protective activity due to its function as blocking 
antibody through mechanisms of competition for allergen between IgG4 and cell‐bound IgE 
antibodies [6]. Thus, the role of specific serum IgG subclasses, particularly IgG4, might be 
considered as a good marker of protective or blocking antibody that may be useful for moni‐
toring activation of tolerance‐inducing mechanisms in patients under AIT.
Therefore, it becomes particularly interesting the development of a method for quantifying 
IgG subclasses against clinically relevant allergens. These antibodies can be detected in the 
serum or other biological fluids, such as saliva from patients with allergic respiratory dis‐
ease using an immunoenzymatic technique (reverse ELISA) and allergen component‐specific 
monoclonal antibodies for monitoring patients under AIT. This assay represents a potential 
tool for monitoring patients with respiratory allergy, especially during AIT.
2. Allergic response
2.1. Sensitization phase
The balance of the different subsets of T helper cells such as Th1, Th2 and Treg with their 
cytokine profiles supports the maintenance of the homeostasis of the immune system. The 
breakdown of this balance among Th1, Th2 and Treg cells leads to excessive activation of Th1 
or Th2 cells, culminating in the development of autoimmune diseases or induction of IgE‐
mediated allergic diseases, respectively [2]. Allergies are one of the most prevalent diseases 
in the world, once they are a result of a breakdown in the immune tolerance that individuals 
usually have to food, inhalant and insect venom allergens [7, 8]. These diseases have a mecha‐
nism of response based on an interaction of the innate and adaptive immune system, with 
interaction of various cell types, cytokines, chemokines and costimulatory signals responsible 
for different T‐cell responses [9].
Th2‐cell subset is induced in a classical respiratory allergic disease, triggering a pathogenesis 
related to several indoor or outdoor inhalant allergens as excretions of house dust mite and 
cockroaches, animal dander, pollens and fungal spores, among others [10]. In addition, the 
dose and function of the allergen are relevant for allergic sensitization [7]. This step is the first 
event of the classical pathogenesis, which is mediated by producing specific IgE antibodies 
directed to epitopes derived from inhalant allergens through the development of Th2 cells. 
First of all, the allergens can pass through the epithelial tissue cells of the respiratory tract 
or directly bind in receptors of innate immune cells. Then, allergens are uptaken and pro‐
cessed by professional antigen‐presenting cells (APCs), as dendritic cells (DCs), that present 
peptides through class II major histocompatibility complexes (MHC II) to naive CD4+ T cells 
located in the submucosal layer, driving to effector and memory T cells of the Th2 phenotype 
(Figure 1) [11]. For that, APCs mediate the production and secretion of crucial cytokines as 
IL‐4, characterizing the occurrence of the third signal of the immune response, which will be 
responsible for the STAT‐6 activation and subsequently GATA‐3 (GATA‐binding protein 3 
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transcription factor) upregulation [12]. Besides the antigenic peptide presentation (first signal 
of the immune response), the participation of costimulatory molecules (second signal) is nec‐
essary to reach the development of Th2 cells by increasing the expression of genes encoded 
on 5q31‐33 chromosome (Figure 1). These genes are associated to IL‐3, IL‐4, IL‐5, IL‐9, IL‐13 
cytokines and granulocyte‐macrophage colony stimulating factor (GM‐CSF) codification, 
related to Th2 pathway [13]. Some of these cytokines, such as IL‐4 and IL‐13, are responsible 
for switching the antibody class on B cell to induce the synthesis of IgE antibodies, which 
bind certain target cells that possess Fc epsilon receptor (FcεR) type I (high‐affinity) or type II 
(low‐affinity) on their membranes like mast cells and basophils, leading to the establishment 
of the sensitization phase [14].
Some allergens, as proteolytic protein or lipopolysaccharide (LPS), can stimulate other bias of 
Th2 response, once the linkage of proteolytic allergens to pattern recognition receptors (PRRs) 
like protease‐activator receptors (PARs), or a linkage of LPS to toll‐like receptors (TLRs), both 
localized in barrier epithelial cells, or even the production of reactive oxygen species (ROS) 
by damaged cells can promote various effects that drive to a proinflammatory response. For 
instance, PARs and TLRs can be a trigger to epithelial cells to produce cytokines, like thymic 
stromal lymphopoietin (TSLP), interleukin‐25 (IL‐25) and IL‐33 related to allergic inflamma‐
tion (Figure 1) [15, 16]. IL‐25 and IL‐33 can upregulate NFκ‐B, together with TSLP that activate 
Figure 1. Innate and adaptive allergic immune response. Sequential events for allergen sensitization and triggering the 
immune response that generates different allergic diseases depending on the affected organs are shown. CD4+: cluster 
of differentiation 4; DC: dendritic cell; GATA‐3: GATA‐binding protein 3 transcription factor; ILC2: group 2 innate 
lymphoid cell; LPS: lipopolysaccharide; NF‐κB: nuclear factor kappa B; PAR: protease‐activated receptor; STAT‐5: signal 
transducer and activator of transcription 5; STAT‐6: signal transducer and activator of transcription 6; TLR4: Toll‐like 
receptor type 4; TSLP: thymic stromal lymphopoietin.
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STAT‐5 promoting an increase of Th2 genes regulation. This way stimulates the production of 
chemokines and cytokine release that contribute to cell migration, especially DCs, basophils 
and eosinophils as well as group 2 innate lymphoid cells (ILC2) involved in allergic responses 
(Figure 1) [17, 18].
Taken together, there are mechanisms that promote a Th2 pathway by GATA‐3 upregulation 
induced especially by IL‐4‐activated STAT‐6, or a Th2 route in which GATA‐3 expression 
is induced in an IL‐4 and STAT‐6‐independent manner [2]. Thus, the maintenance of Th2 
responses by environmental allergens is related to the type of recognition of the allergens 
in the epithelial barrier, which promotes the linkage of innate and adaptive responses [19].
2.2. Effector phase
Allergic subjects besides mast cells and eosinophils with a greater number of IgE receptors, 
have an increase of IgE‐producing B cells stimulated by IL‐4 and IL‐13‐secreting Th2 sub‐
set [20]. In a subsequent contact with allergens that contain genuine‐ or cross‐reactive epit‐
opes capable to cross‐link IgE bound to target cells, calcium‐dependent activation of these 
cells can occur with release of preformed vasoactive mediators as histamine responsible 
for the early phase symptoms and newly formed vasoactive mediators like leukotrienes 
and cytokines for late phase symptoms (Figure 1) [21]. These mediators are character‐
ized by the maintenance of long‐lasting symptoms due to the continued tissue inflamma‐
tion and injury, characterizing typically the type I hypersensitivity reaction. Therefore, 
maturation of eosinophils induced especially by IL‐5 and basophils by IL‐3 and IL‐4 are 
the main secreting effector cells of inflammatory mediators observed in the classical aller‐
gic response [12]. Local symptoms or systemic anaphylaxis may be observed depending 
the affected organ and tissues in a particular individual response to sensitized allergens 
(Figure 1) [21].
The intensity of the immune response to allergens is crucial to develop an allergic condi‐
tion mediated by IgE antibody, or a healthy condition depending on the individual gene 
susceptibility, environmental pollutants, features of allergens, among others [22–24]. Other 
antibody classes have been analyzed because of this variation of response between allergic 
and healthy subjects, such as IgA and IgG subclasses [23–25]. In healthy individuals, B cell 
response to house dust mite allergens ranges from no response to predominantly production 
of IgG antibodies specific to allergens, particularly IgG1 or IgG4 subclass, in the absence or 
low concentration of IgE. Differently, IgG levels, particularly IgG4 subclass, have also been 
detected in allergic subjects in addition to high levels of IgE, but IgG1 levels have been found 
at similar levels in both healthy and allergic individuals [26, 27].
3. Cellular and molecular mechanisms of AIT
Allergen‐specific immunotherapy (AIT) is performed by the administration of increasing con‐
centrations of allergens (build‐up phase) up to maintenance doses, mainly given by subcuta‐
neous, epicutaneous, oral, sublingual, or recently by intralymphatic route. AIT aims to induce 
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changes on the immune response of allergic individuals, drawing a state of allergen‐specific 
tolerance, which contributes with a curative effect for a long period of time [28–32].
The cellular and molecular mechanisms of AIT are diverse, involving the very early mast cell 
and basophil desensitization, effect on antigen‐presenting cells, modulation of T and B cell 
repertories as well as modification of allergen‐specific antibody responses (Figure 2) [32].
Although AIT reduces the allergic inflammation mediated by IgE‐dependent mechanism over 
the time, a very early effect on basophil and mast cell activation status is observed just after 
the initiation of the therapeutic regimen, leading to a lower risk to develop anaphylactic mani‐
festations [33–35]. The subjacent mechanism of basophil and mast cell desensitization has 
not been elucidated yet; however, some clues highlight this issue. AIT leads to a controlled 
releasing of histamine and leukotrienes by basophil and mast cells after allergen adminis‐
tration, producing a gradual reduction of granule content of the inflammatory mediators in 
these cells in patients submitted to immunotherapy [31, 33, 36], although there is not a direct 
evidence of diminution of intracellular vasoactive mediator amount by histological analy‐
sis. Short‐term venom immunotherapy induces desensitization of FcεRI‐mediated basophil 
response. The levels of mRNA and FcεRI cell‐surface expression decreased in basophil cells 
from patients submitted to venom immunotherapy, indicating that the reduction in FcεRI 
Figure 2. Immunological changes induced by allergen‐specific immunotherapy (AIT). Desensitization of basophil/
mast cells and upregulation of markers associated with dendritic cells (DCs) driving differentiation of IL‐10‐producing 
Treg and Breg cells and subsequent activation of B cells to synthesize allergen‐blocking factors, particularly IgG4 and 
suppression of IgE antibodies during AIT are shown. AIT: allergen‐specific immunotherapy; Breg cell: regulatory B 
cell; CTLA‐4: cytotoxic T lymphocyte antigen‐4; DC: dendritic cell; FcεRI: high‐affinity receptor for the Fc region of 
immunoglobulin E (IgE); H2R: histamine H2 receptor; PD1: programmed death‐1 receptor; PDL1: programmed death 
ligand‐1; SCIT: subcutaneous immunotherapy; ORAL/SLIT: oral/sublingual immunotherapy; Treg cell: regulatory T cell.
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expression contributes to the phenomenon of the early basophil desensitization observed 
after AIT [37, 38]. On the other hand, AIT also provokes an allergen‐mediated upregulation 
of the type 2 histamine receptor (H2R) gene, which was associated with the suppression of 
FcεRI‐mediated basophil activation, inducing a tolerogenic response (Figure 2) [34, 39]. The 
engagement of H2R with its agonists prevents further histamine and leukotriene releasing as 
well as IL‐4 and IL‐8 production by basophil cells [34]. The molecular mechanism involved 
in H2R‐dependent basophil desensitization is supposed to be mediated by the cAMP path‐
way because the stimulation with H2R agonist or with a direct cAMP inducer was able to 
inhibit the FcεRI‐mediated basophil activation [34]. In this way, the increase of concentration 
of cAMP activates PKA (Protein Kinase A, the principal intracellular target of cAMP), which 
in turn decreases the intracellular calcium influx, thus preventing FcεRI‐dependent basophil 
and mast cell degranulation [22].
Antigen‐presenting cells, particularly dendritic cells (DC), display an important role in the 
induction of allergic diseases driving Th2 responses and the IgE‐dependent pathophysiologic 
mechanism. Some evidences reveal that AIT can affect directly the phenotype of the anti‐
gen‐presenting cells correlating with clinical improvement in patients with allergic diseases 
[40–42]. A regulatory dendritic cell signature correlating with the clinical efficacy after aller‐
gen‐specific sublingual immunotherapy (SLIT) has been observed in peripheral blood mono‐
nuclear cells (PBMCs) from clinical allergic responders in comparison with nonresponders 
or patients that received only placebo [40]. Likewise, a report using transcriptomic and pro‐
teomic approaches demonstrated that PBMCs from allergic patients downregulate the expres‐
sion of markers related with DC driving the differentiation of Th2 cells, whereas upregulate 
markers associated with DC driving differentiation of T regulatory cells, after only 4 months 
of SLIT. These results indicate that AIT has an early effect on antigen‐presenting cells that 
trigger the Th2 downregulation [42]. Therefore, the changes evoked during AIT regimen on 
antigen‐presenting cells, with a predominance of DC tolerogenic subsets inducing the devel‐
opment of T regulatory (Treg) cells, may be part of the mechanism behind of the therapeutic 
efficacy observed in AIT (Figure 2).
The induction of the allergen‐specific tolerance is a pivotal event required in AIT procedures 
by generating allergen‐specific Treg cells [43], responsible for maintaining immune homeo‐
stasis. Treg cells have been characterized by stable expression of CD25, CD4 and FOXP3 
(Forkhead box protein 3), expression of suppressive surface molecules, such as cytotoxic T 
lymphocyte antigen‐4 (CTLA‐4) and programed death 1 (PD1) and secretion of IL‐10 and 
TGF‐β cytokines [31]. Accordingly, increased numbers of Treg cells were also detected in 
nasal mucosa correlating with clinical efficacy after AIT, supporting the importance of these 
cells on tolerogenic phenomenon observed in patients upon AIT [44].
TGF‐β produced by Treg cells is a potent inhibitor of Th2, Th1 and Th17 effector response and 
has been associated with the suppression of seasonal allergic inflammation [31] and produc‐
tion of mucosal allergen‐specific IgA after AIT [30, 45, 46]. Likewise, IL‐10 produced by Tr1, 
Treg and Breg cells were markedly increased after AIT in allergic individuals and those cells 
were also associated with suppressor effect observed in several immunotherapeutical proto‐
cols [47–49].
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IL‐10 acts as a potent suppressor cytokine, reducing the production of proinflammatory cyto‐
kines by mast cells, decreasing the eosinophil functions and also downregulating the expres‐
sion of MHC class II and costimulatory molecules on surface of monocytes/macrophages and 
DCs, thus preventing allergen‐induced Th2 activation [50–53]. Importantly, IL‐10 is related 
with the antibody class switch on B cells, favoring the production of IgG4 subclass, a dominant 
antibody subclass in late phase response of AIT, which is associated with a gradual decreasing 
of IgE levels. Alternatively, AIT can also provoke immune deviation from Th2 in favor of Th1 
responses that culminate in the production of IFN‐γ, inducing preferentially B cells to produce 
IgG1 subclass directed to allergenic components present in the formulation of the AIT [31].
Therefore, allergen‐specific IgG antibodies induced during AIT may act as blocking antibodies, 
reflecting in the reduction of mast cell activation and degranulation due to its competition with 
IgE antibodies for allergen binding and inhibiting IgE‐facilitated allergen presentation [54].
4. Immunotherapy follow‐up
In addition to clinical parameters like improvement in symptoms and medication scores that 
are subjective, it should be very helpful if the medical assistant had also objective parameters 
such as complementary laboratorial tests for the follow‐up of allergic patients under AIT.
Considering the several cellular and molecular mechanisms involved in AIT described before, 
such as the determination of the type 2 histamine receptor (H2R), basophil activation test, 
or a procedure for measuring regulatory dendritic cell signature, all of which can be cor‐
related with the clinical efficacy of AIT, it becomes evident that complex methods should be 
employed and certainly would be difficult to be applied in the routine analysis.
Therefore, we can accomplish that measurement of specific IgG, particularly of the IgG4 sub‐
class, might be used for monitoring patients receiving AIT, since it will be more simple and 
feasible in any clinical analysis laboratory. In this context, a previous study has demonstrated 
a lack of correlation between venom‐specific total IgG levels and prediction of systemic reac‐
tions, concluding that measuring specific IgG antibodies is not useful for monitoring AIT. In 
this study, the authors postulated that IgG subclasses could be probably involved, since the 
clinical improvement is not necessarily reflected in the total IgG antibody titre [55]. However, 
other investigators have found a correlation between low levels of venom‐specific IgG and a 
greater risk of anaphylaxis in patients submitted to venom allergen immunotherapy during 
4 years and the opposite was also true, a lower risk of systemic reaction could be observed 
in those patients with high levels of venom‐specific IgG, concluding that the measurement 
of specific IgG is useful and beneficial, especially for advising greater risk of anaphylaxis 
in patients who present low levels of specific IgG [56]. An interpretation that we can point 
out is the existence of two groups of patients who are receiving AIT; one group includes the 
good responders and another those patients that are non‐ or low‐responders and such fact 
can be associated to their intrinsic genetic features, particularly related to the specific type of 
HLA (human leukocyte antigen). Also, we need to consider the presence of pre‐existing lev‐
els of allergen‐specific IgG subclasses before AIT, since the patients themselves may present 
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stimulation of their immune system for attempting to synthesize blocking antibodies as an 
autoregulatory mechanism.
Recent experimental study using a high‐dose cutaneous exposure to Dermatophagoides 
 pteronyssinus mite extract has shown to induce effective blocking IgG production, support‐
ing that the detection of increased IgG antibody titres is a promisor marker of clinical effi‐
cacy of AIT [57].
In addition, a study employing a nonclassical allergen intralymphatic immunotherapy using 
a modular antigen transporter Fel d 1 (MAT‐Fel d 1) has found a strong increase in allergen‐
specific IgG4 levels and some increase in IgG2 antibody subclasses, but this procedure was 
not able to stimulate the production of IgG1 and IgG3 subclasses [58].
The production of specific IgG antibodies to allergens, especially IgG4 subclass, is the most 
important immunological change induced by AIT [59–62]. However, in some studies there 
is a lack of correlation between increased IgG4 titres and clinical improvement [55], since 
the induction of IgG4 blocking antibodies may not be reflected in serum or other biological 
fluid samples, requiring bioassays as the inhibition of IgE‐facilitated allergen presentation 
for its possible detection [63]. Accordingly, production of specific IgG4 antibodies to relevant 
allergenic components has been associated with the protective activity due to its function as 
blocking antibody through mechanisms of competition for allergen between IgG4 and cell‐
bound IgE antibodies [6]. In this context, several other investigators have found that clinical 
improvement after mite AIT was associated with increased levels of serum specific IgG4 or 
ratio of specific IgG4/IgG1 [64–66].
Unfortunately, there is no current routine laboratorial test for the detection of allergen‐spe‐
cific IgG antibodies, particularly IgG1 and IgG4 subclasses, against crude allergen extract 
and/or clinically relevant allergen components that could be used as a useful tool for monitor‐
ing AIT. Physicians, who assist patients with respiratory allergy that have been submitted to 
AIT, are following the treatment of such patients only by clinical parameters (symptoms and 
medication scores) that are very subjective. The possibility of following such patients under 
AIT using allergen‐specific IgG1 and/or IgG4 antibody measurements will enable to monitor 
those patients by using objective parameters in association with subjective clinical param‐
eters. This fact has stimulated researchers to develop objective methods for quantifying those 
allergen‐specific IgG antibodies.
In 2001, our group has developed a reverse ELISA technique for quantifying Der p 2 allergen‐
specific IgE antibodies, using capture Der p 2‐specific monoclonal antibodies. This technique 
was developed with the intention of helping the allergy diagnosis by means of a molecular 
allergen component, since the presence of Der p 2 allergen‐specific IgE antibodies indicates 
the occurrence of an allergic response in the patient. It has also been demonstrated that this 
technique has a higher sensitivity related to conventional ELISA [67].
On the other hand, the detection of specific IgG antibodies or particularly IgG1 and IgG4 
subclasses, against Der p 2, or against any other specific allergenic component, would 
indicate the development of a physiological response, i.e., a defense response against dust 
mite allergens.
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Thus, on the basis of the information described above, it becomes particularly interesting to 
develop a method for quantifying IgG antibody subclasses against clinically relevant aller‐
gens. These antibodies can be detected in the serum or other biological fluids, such as saliva 
from patients with allergic respiratory disease using an immunoenzymatic technique (reverse 
ELISA) and relevant monoclonal antibodies for monitoring patients under AIT.
5. Method for measuring allergen‐specific IgG subclasses
Part of our group has developed a reverse ELISA technique as described in the European 
patent application registered as EP 2232265, providing a method for measuring allergen‐
specific IgG antibody subclasses, including IgG1, IgG2, IgG3 and IgG4, for monitoring 
patients with allergic diseases under AIT [68]. As illustrated in Figure 3, allergen‐specific 
monoclonal antibodies, for example, anti‐Der p 1 or anti‐Der p 2, are bound to ELISA 
microtitration plates in order to capture the corresponding natural allergens, Der p 1 or Der 
p 2, respectively, present in the crude D. pteronyssinus extract, which subsequently inter‐
acts with specific IgG antibodies existent in serum samples or other biological fluids from 
allergic patients. Those antibodies are later detected by the addition of mouse monoclonal 
antibodies, against human IgG subclasses, preferentially IgG4, labeled with biotin and, sub‐
sequently are incubated with the streptavidin‐peroxidase enzymatic conjugate. Reaction 
is revealed by the addition of the enzymatic substrate (hydrogen peroxide) diluted in a 
chromogenic buffer [2,2′‐azino‐bis(3‐ethylbenzthiazoline‐6‐sulphonic acid) – ABTS] and 
absorbance is determined in a microtitration plate reader, at 405 nm.
Figure 3. Representative diagram (sequential steps A to F) of the reverse enzyme‐linked immunosorbent assay (ELISA). 
(1) Capture allergen‐specific (Der p 1 or Der p 2) monoclonal antibody; (2) crude Dermatophagoides pteronyssinus extract; 
(3) allergen (Der p 1 or Der p 2) present in crude extract; (4) allergen‐specific IgG antibody present in serum samples 
or other biological fluids from allergic patients; (5) monoclonal antibody against human IgG subclass (preferentially 
IgG4) labeled with biotin; (6) streptavidin‐peroxidase enzymatic conjugate; (7) reaction is revealed by the addition of 
enzymatic substrate (hydrogen peroxide) diluted in a chromogenic buffer (ABTS) and absorbance is determined in a 
plate reader at 405 nm (Taketomi EA and Silva DAO, 2016, found in European Patent Office EP 2232265 [68]).
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The reverse ELISA (rELISA) technique for the detection of IgG antibody subclasses has a great 
advantage over others that use indirect ELISA [69, 70]. It does not require purified allergens or 
antigens, which are often too expensive or difficult to obtain in a purified and isolated form, since 
the natural allergen components present in the crude allergen extract are bound on the microti‐
tration plate by the capture allergen‐specific monoclonal antibody. Another advantage of this 
assay is that it does not require specific and exclusive equipment, avoiding a direct dependence 
between the producers of the diagnostic kits or the diagnostic equipment and the consumers.
The rELISA assay also demonstrated higher sensitivity than the conventional ELISA (cELISA) 
in the measurement of allergen‐specific IgG subclasses, particularly IgG4 antibodies, to the 
crude D. pteronyssinus (Dpt) extract and its major allergens (Der p 1 and Der p 2), using a pool 
of reference sera obtained from mite‐allergic patients (Figure 4). The sensitivity of each assay 
was 15.6 EU/mL for cELISA‐Dpt, 1.9 EU/mL for rELISA‐Der p 1 and 7.8 EU/mL for rELISA‐
Der p 2. Likewise, specificity of rELISA for the measurement of allergen‐specific IgG sub‐
classes, particularly IgG4 antibodies to the major allergens (Der p 1 and Der p 2) was shown 
Figure 4. Sensitivity of cELISA and rELISA for the measurement of IgG4 antibodies to the crude extract of Dermatophagoides 
pteronyssinus (Dpt) and its major allergens (Der p 1 and Der p 2). The sensitivity of each assay is indicated by the asterisk 
(Taketomi EA and Silva DAO, 2016, found in European Patent Office EP 2232265 [68]).
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to be higher than cELISA for the detection of IgG4 to crude Dpt extract as determined by inhi‐
bition assays (Figure 5). All assays showed a dose‐dependent manner inhibition when a pool 
of reference sera containing allergen‐specific IgG4 antibodies was incubated with increasing 
concentrations (0.15–15,000 AU/mL) of the crude Dpt extract as inhibitor antigen. Inhibition 
was higher than 80% for all assays, with 88% for cELISA‐Dpt, 82% for rELISA‐Der p 1 and 
89% for rELISA‐Der p 2, when the highest concentration of Dpt allergen extract was used.
In our previous study [71], rELISA was also employed for monitoring specific IgG4 levels to 
D. pteronyssinus major allergens (Der p 1 and Der p 2) along with cELISA for measuring IgG4 
levels to crude Dpt extract in serum samples of two groups of mite‐allergic patients under 
AIT by subcutaneous route: one active DPT group, receiving the D. pteronyssinus extract and 
another placebo group. Serum samples were analyzed in two time‐points, day 0 and after 1 
year of treatment. As shown in Figure 6, patients of the active group (DPT) had increased 
levels of IgG4 to D. pteronyssinus extract and its major allergens, particularly to the Der p 1 
allergen component, after 1 year of therapy as compared to patients without active immu‐
notherapy (placebo group). Also, there was a significant increase of serum IgG1 levels to D. 
pteronyssinus extract and Der p 1 allergen component in patients that had received active 
immunotherapy in contrast with those patients belonging to the placebo group [71].
Furthermore, we were also able to show a significant increase in IgG1 and IgG4 levels to D. 
pteronyssinus, Der p 1 or Der p 2 allergen components after 12 and 18 months of sublingual 
immunotherapy using D. pteronyssinus extract. In contrast, patients receiving placebo did not 
Figure 5. cELISA and rELISA specificity for IgG4 antibodies to the crude extract of Dermatophagoides pteronyssinus 
(Dpt) and its major allergens (Der p 1 and Der p 2) using competitive inhibition assays. Mite‐allergic patient sera were 
preadsorbed with different concentrations of Dpt inhibitor antigen and then assayed in each cELISA and rELISA for 
measurement of specific IgG4 antibodies. Data represent the percentage of inhibition in each assay (Taketomi EA and 
Silva DAO, 2016, found in European Patent Office EP 2232265 [68]).
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Figure 6. Levels of IgG4 antibodies to the crude extract of Dermatophagoides pteronyssinus (Dpt) and its major allergens 
(Der p 1 and Der p 2) determined by cELISA and rELISA in sera from patients randomized to two treatment groups: 
(A) active DPT (Dpt extract; n = 15) and (B) Placebo (n = 15). Antibody levels are expressed in ELISA indices (EI) as 
individual values on day 0 and after 1 year of treatment and connected with a line; the mean EI values for each of those 
two time‐points are also indicated. Significant differences before and after treatment within the groups were determined 
by the Wilcoxon signed‐rank test (Taketomi EA and Silva DAO, 2016, found in European Patent Office EP 2232265 [68]).
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show any increases in IgG1 or IgG4 antibody levels to crude D. pteronyssinus extract or its 
major allergen components in that studied period of time [30].
Thus, our studies have shown that increased levels of allergen‐specific IgG subclasses, par‐
ticularly IgG4 and IgG1, can be detected after variable period of AIT in the serum of patients 
receiving mite AIT, using major natural components in the ELISA technique that allow better 
reaction than their modified or recombinant counterparts without the need of purified aller‐
gen components. For this reason, the measurement of specific serum IgG subclasses, particu‐
larly IgG4, should be considered as a good marker of protective or blocking antibody that may 
be useful for monitoring activation of tolerance‐inducing mechanisms in patients under AIT.
Therefore, according to the results described above, reverse ELISA has shown to be a sensitive 
and alternative method for measuring natural allergen‐specific serum IgG antibody subclasses, 
especially IgG4, providing valuable information for monitoring patients with allergic respira‐
tory disease during AIT with peptides or native or recombinant allergens of clinical relevance.
6. Conclusion
We can conclude that IgE‐mediated allergic patients submitted to AIT usually demonstrate 
immunological changes, in particular, induction of allergen‐specific IgG that may act as block‐
ing factors competing with IgE antibodies and thus contributing for ameliorating the clinical 
symptoms. In this context, we recommend follow these patients under AIT using clinical (symp‐
toms and medication scores) and laboratorial (allergen‐specific IgG subclass measurement) 
parameters since this technique has shown to be a potential tool for monitoring these patients.
Acknowledgements
We thank the following Brazilian funding agencies: CAPES (Coordenação de Aperfeiçoamento 
de Pessoal de Nível Superior, Brasília, DF), CNPq (Conselho Nacional de Pesquisa e 
Desenvolvimento, Brasília, DF) and FAPEMIG (Fundação de Amparo à Pesquisa do Estado de 
Minas Gerais, Belo Horizonte, MG). We also thank the Post‐Graduation Program in Applied 
Immunology and Parasitology of the Federal University of Uberlandia for the payment of the 
article processing charge.
Author details
Ernesto Akio Taketomi*, Juliana Silva Miranda, Jair Pereira da Cunha‐Júnior and Deise 
Aparecida de Oliveira Silva
*Address all correspondence to: etaketomi@gmail.com
Laboratory of Allergy and Clinical Immunology, Department of Immunology, Institute of 
Biomedical Sciences, Federal University of Uberlandia, Uberlandia, Brazil
Immunotherapy - Myths, Reality, Ideas, Future394
References
[1] Akdis M, Akdis CA. Therapeutic manipulation of immune tolerance in allergic disease. 
Nature reviews drug discovery. 2009;8:645–660. DOI: 10.1038/nrd2653
[2] Paul WE, Zhu J. How are T(H)2‐type immune responses initiated and amplified? Nature 
Reviews Immunology. 2010;10:225–235. DOI: 10.1038/nri2735
[3] Wynn TA. Type 2 cytokines: mechanisms and therapeutic strategies. Nature Reviews 
Immunology. 2015;15:271–282. DOI: 10.1038/nri3831
[4] Matsuoka T, Shamji MH, Durham SR. Allergen immunotherapy and tolerance. Allergo‐
lo gy International: Official Journal of the Japanese Society of Allergology. 2013;62:403–
413. DOI: 10.2332/allergolint.13‐RAI‐0650
[5] Thomas WR. House dust mite allergens: new discoveries and relevance to the allergic 
patient. Current Allergy and Asthma Reports. 2016;16:69. DOI: 10.1007/s11882‐016‐ 
0649‐y
[6] Aalberse RC, Stapel SO, Schuurman J, Rispens T. Immunoglobulin G4: an odd antibody. 
Clinical and Experimental Allergy: Journal of the British Society for Allergy and Clinical 
Immunology. 2009;39:469–477. DOI: 10.1111/j.1365‐2222.2009.03207.x
[7] Traidl‐Hoffmann C, Jakob T, Behrendt H. Determinants of allergenicity. The Journal of 
Allergy and Clinical Immunology. 2009;123:558–566. DOI: 10.1016/j.jaci.2008.12.003
[8] Calderon MA, Casale TB, Togias A, Bousquet J, Durham SR, Demoly P. Allergen‐spe‐
cific immunotherapy for respiratory allergies: from meta‐analysis to registration and 
beyond. The Journal of Allergy and Clinical Immunology. 2011;127:30–38. DOI: 10.1016/j.
jaci.2010.08.024
[9] Jutel M, Akdis CA. T‐cell subset regulation in atopy. Current Allergy and Asthma 
Reports. 2011;11:139–145. DOI: 10.1007/s11882‐011‐0178‐7
[10] Shakib F, Ghaemmaghami AM, Sewell HF. The molecular basis of allergenicity. Trends 
in Immunology. 2008;29:633–642. DOI: 10.1016/j.it.2008.08.007
[11] Holgate ST. Innate and adaptive immune responses in asthma. Nature Medicine. 
2012;18:673–683. DOI: 10.1038/nm.2731
[12] Holgate ST, Polosa R. Treatment strategies for allergy and asthma. Nature Reviews 
Immunology. 2008;8:218–230. DOI: 10.1038/nri2262
[13] Cousins DJ, Lee TH, Staynov DZ. Cytokine coexpression during human Th1/Th2 cell 
differentiation: direct evidence for coordinated expression of Th2 cytokines. Journal of 
Immunology. 2002;169:2498–2506. DOI: 10.4049/jimmunol.169.5.2498
[14] Wu LC, Scheerens H. Targeting IgE production in mice and humans. Current Opinion in 
Immunology. 2014;31:8–15. DOI: 10.1016/j.coi.2014.08.001
[15] Bulek K, Swaidani S, Aronica M, Li X. Epithelium: the interplay between innate and Th2 
immunity. Immunology and Cell Biology. 2010;88:257–268. DOI: 10.1038/icb.2009.113
Allergen-Specific Immunotherapy Follow-Up by Measuring Allergen-Specific IgG as an Objective Parameter
http://dx.doi.org/10.5772/66711
395
[16] Georas SN, Rezaee F. Epithelial barrier function: at the front line of asthma immunol‐
ogy and allergic airway inflammation. The Journal of Allergy and Clinical Immunology. 
2014;134:509–520. DOI: 10.1016/j.jaci.2014.05.049
[17] Lambrecht BN, Hammad H. Allergens and the airway epithelium response: gateway to 
allergic sensitization. The Journal of Allergy and Clinical Immunology. 2014;134:499–
507. DOI: 10.1016/j.jaci.2014.06.036
[18] Divekar R, Kita H. Recent advances in epithelium‐derived cytokines (IL‐33, IL‐25 and 
thymic stromal lymphopoietin) and allergic inflammation. Current Opinion in Allergy 
and Clinical Immunology. 2015;15:98–103. DOI: 10.1097/ACI.0000000000000133
[19] Romeo MJ, Agrawal R, Pomes A, Woodfolk JA. A molecular perspective on TH2‐pro‐
moting cytokine receptors in patients with allergic disease. The Journal of Allergy and 
Clinical Immunology. 2014;133:952–960. DOI: 10.1016/j.jaci.2013.08.006
[20] van Ree R, Hummelshoj L, Plantinga M, Poulsen LK, Swindle E. Allergic sensiti‐
zation: host‐immune factors. Clinical and Translational Allergy. 2014;4:1–9. DOI: 
10.1186/2045‐7022‐4‐12
[21] Ravetch JV, Kinet JP. Fc receptors. Annual Review of Immunology. 1991;9:457–492. DOI: 
10.1146/annurev.iy.09.040191.002325
[22] Serra‐Pages M, Olivera A, Torres R, Picado C, Mora F, Rivera J. E‐prostanoid 2 recep‐
tors dampen mast cell degranulation via cAMP/PKA‐mediated suppression of IgE‐
dependent signaling. Journal of Leukocyte Biology. 2012;92:1155–1165. DOI: 10.1189/
jlb.0212109
[23] Batard T, Hrabina A, Bi XZ, Chabre H, Lemoine P, Couret MN, et al. Production and 
proteomic characterization of pharmaceutical‐grade Dermatophagoides pteronyssinus and 
Dermatophagoides farinae extracts for allergy vaccines. International Archives of Allergy 
and Immunology. 2006;140:295–305. DOI: 10.1159/000093707
[24] Jackola DR, Pierson‐Mullany LK, Liebeler CL, Blumenthal MN, Rosenberg A. Variable 
binding affinities for allergen suggest a ‘selective competition’ among immunoglobu‐
lins in atopic and non‐atopic humans. Molecular Immunology. 2002;39:367–377. DOI: 
10.1016/S0161‐5890(02)00108‐6
[25] Batard T, Basuyaux B, Laroze A, Lambin P, Bremard‐Oury C, Aucouturier P, et al. Isotypic 
analysis of grass‐pollen‐specific immunoglobulins in human plasma. 2. Quantification 
of the IgE, IgM, IgA class and the IgG subclass antibodies. International Archives of 
Allergy and Immunology. 1993;102:279–287. DOI: 10.1111/j.1365‐2222.1996.tb00528.x
[26] Akdis M. Healthy immune response to allergens: T regulatory cells and more. Current 
Opinion in Immunology. 2006;18:738–744. DOI: 10.1016/j.coi.2006.06.003
[27] Kemeny DM, Urbanek R, Ewan P, McHugh S, Richards D, Patel S, et al. The subclass of 
IgG antibody in allergic disease: II. The IgG subclass of antibodies produced following 
natural exposure to dust mite and grass pollen in atopic and non‐atopic individuals. 
Immunotherapy - Myths, Reality, Ideas, Future396
Clinical and Experimental Allergy: Journal of the British Society for Allergy and Clinical 
Immunology. 1989;19:545–549. DOI: 10.1111/j.1365‐2222.1989.tb02431.x
[28] Senti G, Prinz Vavricka BM, Erdmann I, Diaz MI, Markus R, McCormack SJ, et al. 
Intralymphatic allergen administration renders specific immunotherapy faster and 
safer: a randomized controlled trial. Proceedings of the National Academy of Sciences 
of the United States of America. 2008;105:17908–17912. DOI: 10.1073/pnas.0803725105
[29] Senti G, Graf N, Haug S, Ruedi N, von Moos S, Sonderegger T, et al. Epicutaneous aller‐
gen administration as a novel method of allergen‐specific immunotherapy. The Journal 
of Allergy and Clinical Immunology. 2009;124:997–1002. DOI: 10.1016/j.jaci.2009.07.019
[30] Queiros MG, Silva DA, Siman IL, Ynoue LH, Araujo NS, Pereira FL, et al. Modulation 
of mucosal/systemic antibody response after sublingual immunotherapy in mite‐aller‐
gic children. Pediatric Allergy and Immunology: Official Publication of the European 
Society of Pediatric Allergy and Immunology. 2013;24:752–761. DOI: 10.1111/pai.12163
[31] Akdis CA, Akdis M. Mechanisms of allergen‐specific immunotherapy and immune tol‐
erance to allergens. The World Allergy Organization Journal. 2015;8:17. DOI: 10.1186/
s40413‐015‐0063‐2
[32] Schmid JM, Nezam H, Madsen HH, Schmitz A, Hoffmann HJ. Intralymphatic immu‐
notherapy induces allergen specific plasmablasts and increases tolerance to skin prick 
testing in a pilot study. Clinical and Translational Allergy. 2016;6:19. DOI: 10.1186/
s13601‐016‐0107‐x
[33] Jutel M, Muller UR, Fricker M, Rihs S, Pichler WJ, Dahinden C. Influence of bee venom 
immunotherapy on degranulation and leukotriene generation in human blood baso‐
phils. Clinical and Experimental Allergy: Journal of the British Society for Allergy and 
Clinical Immunology. 1996;26:1112–1118. DOI: 10.1111/j.1365‐2222.1996.tb00496.x
[34] Novak N, Mete N, Bussmann C, Maintz L, Bieber T, Akdis M, et al. Early suppression 
of basophil activation during allergen‐specific immunotherapy by histamine receptor 2. 
The Journal of Allergy and Clinical Immunology. 2012;130:1153–1158 e2. DOI: 10.1016/j.
jaci.2012.04.039
[35] Erzen R, Kosnik M, Silar M, Korosec P. Basophil response and the induction of a toler‐
ance in venom immunotherapy: a long‐term sting challenge study. Allergy. 2012;67:822–
830. DOI: 10.1111/j.1398‐9995.2012.02817.x
[36] Eberlein‐Konig B, Ullmann S, Thomas P, Przybilla B. Tryptase and histamine release due 
to a sting challenge in bee venom allergic patients treated successfully or unsuccessfully 
with hyposensitization. Clinical and Experimental Allergy: Journal of the British Society 
for Allergy and Clinical Immunology. 1995;25:704–712. DOI: 10.1111/j.1365‐2222.1995.
tb00007.x
[37] Celesnik N, Vesel T, Rijavec M, Silar M, Erzen R, Kosnik M, et al. Short‐term venom 
immunotherapy induces desensitization of FcepsilonRI‐mediated basophil response. 
Allergy. 2012;67:1594–1600. DOI: 10.1111/all.12044
Allergen-Specific Immunotherapy Follow-Up by Measuring Allergen-Specific IgG as an Objective Parameter
http://dx.doi.org/10.5772/66711
397
[38] Celesnik Smodi N, Silar M, Erzen R, Rijavec M, Kosnik M, Korosec P. Down‐regulation of 
FcepsilonRI‐mediated CD63 basophil response during short‐term VIT determined venom‐
nonspecific desensitization. PloS One. 2014;9:e94762. DOI: 10.1371/journal.pone.0094762
[39] Akdis CA, Blaser K. Histamine in the immune regulation of allergic inflammation. 
Journal of Allergy and Clinical Immunology. 2003;112:15–22. DOI: 10.1067/mai.2003.1585
[40] Zimmer A, Bouley J, Le Mignon M, Pliquet E, Horiot S, Turfkruyer M, et al. A regulatory 
dendritic cell signature correlates with the clinical efficacy of allergen‐specific sublingual 
immunotherapy. The Journal of Allergy and Clinical Immunology. 2012;129:1020–1030. 
DOI: 10.1016/j.jaci.2012.02.014
[41] Lundberg K, Rydnert F, Broos S, Andersson M, Greiff L, Lindstedt M. Allergen‐spe‐
cific immunotherapy alters the frequency, as well as the FcR and CLR expression pro‐
files of human dendritic cell subsets. PloS One. 2016;11:e0148838. DOI: 10.1371/journal.
pone.0148838
[42] Gueguen C, Bouley J, Moussu H, Luce S, Duchateau M, Chamot‐Rooke J, et al. Changes 
in markers associated with dendritic cells driving the differentiation of either TH2 cells 
or regulatory T cells correlate with clinical benefit during allergen immunotherapy. 
The Journal of Allergy and Clinical Immunology. 2016;137:545–558. DOI: 10.1016/j.
jaci.2015.09.015
[43] Jutel M, Kosowska A, Smolinska S. Allergen immunotherapy: past, present and 
future. Allergy, Asthma and Immunology Research. 2016;8:191–197. DOI: 10.4168/
aair.2016.8.3.191
[44] Radulovic S, Jacobson MR, Durham SR, Nouri‐Aria KT. Grass pollen immunotherapy 
induces Foxp3‐expressing CD4+ CD25+ cells in the nasal mucosa. The Journal of Allergy 
and Clinical Immunology. 2008;121:1467–1472, 1472. e1. DOI: 10.1016/j.jaci.2008.03.013
[45] Pilette C, Nouri‐Aria KT, Jacobson MR, Wilcock LK, Detry B, Walker SM, et al. Grass 
pollen immunotherapy induces an allergen‐specific IgA2 antibody response associated 
with mucosal TGF‐β expression. The Journal of Immunology. 2007;178:4658–4666. DOI: 
10.4049/jimmunol.178.7.4658
[46] Gloudemans AK, Lambrecht BN, Smits HH. Potential of immunoglobulin A to pre‐
vent allergic asthma. Clinical and Developmental Immunology. 2013;2013:542091. DOI: 
10.1155/2013/542091
[47] Francis JN, Till SJ, Durham SR. Induction of IL‐10+CD4+CD25+ T cells by grass pollen 
immunotherapy. Journal of Allergy and Clinical Immunology. 2003;111:1255–1261. DOI: 
10.1067/mai.2003.1570
[48] Ling EM, Smith T, Nguyen XD, Pridgeon C, Dallman M, Arbery J, et al. Relation of 
CD4+CD25+ regulatory T‐cell suppression of allergen‐driven T‐cell activation to atopic 
status and expression of allergic disease. The Lancet. 2004;363:608–615. DOI: 10.1016/
s0140‐6736(04)15592‐x
Immunotherapy - Myths, Reality, Ideas, Future398
[49] Bohle B, Kinaciyan T, Gerstmayr M, Radakovics A, Jahn‐Schmid B, Ebner C. Sublingual 
immunotherapy induces IL‐10‐producing T regulatory cells, allergen‐specific T‐cell 
tolerance and immune deviation. The Journal of Allergy and Clinical Immunology. 
2007;120:707–713. DOI: 10.1016/j.jaci.2007.06.013
[50] O'Garra A, Vieira PL, Vieira P, Goldfeld AE. IL‐10‐producing and naturally occurring 
CD4+ Tregs: limiting collateral damage. Journal of Clinical Investigation. 2004;114:1372–
1378. DOI: 10.1172/jci23215
[51] Wu K, Bi H, Sun K, Wang C. IL‐10‐producing type 1 regulatory T cells and allergy. 
Cellular and Molecular Immunology. 2007;4:269–275. DOI: 10.1002/9780471773719.
ch13
[52] Taylor A, Akdis M, Joss A, Akkoc T, Wenig R, Colonna M, et al. IL‐10 inhibits CD28 and 
ICOS costimulations of T cells via src homology 2 domain‐containing protein tyrosine 
phosphatase 1. The Journal of Allergy and Clinical Immunology. 2007;120:76–83. DOI: 
10.1016/j.jaci.2007.04.004
[53] Akdis CA, Akdis M. Mechanisms of immune tolerance to allergens: role of IL‐10 
and tregs. The Journal of Clinical Investigation. 2014;124:4678–4680. DOI: 10.1172/
JCI78891
[54] Siman IL, de Aquino LM, Ynoue LH, Miranda JS, Pajuaba AC, Cunha‐Junior JP, et al. 
Allergen‐specific IgG antibodies purified from mite‐allergic patients sera block the IgE 
recognition of Dermatophagoides pteronyssinus antigens: an in vitro study. Clinical and 
Developmental Immunology. 2013;2013:657424. DOI: 10.1155/2013/657424
[55] Ewan PW, Deighton J, Wilson AB, Lachmann PJ. Venom‐specific IgG antibodies in bee and 
wasp allergy: lack of correlation with protection from stings. Clinical and Experimental 
Allergy: Journal of the British Society for Allergy and Clinical Immunology. 1993;23:647–
660. DOI: 10.1111/j.1365‐2222.1993.tb01791.x
[56] Golden DB, Lawrence ID, Hamilton RH, Kagey‐Sobotka A, Valentine MD, Lichtenstein 
LM. Clinical correlation of the venom‐specific IgG antibody level during maintenance 
venom immunotherapy. The Journal of Allergy and Clinical Immunology. 1992;90:386–
393. DOI: 10.1016/S0091‐6749(05)80019‐3
[57] Hirai T, Yoshioka Y, Takahashi H, Handa T, Izumi N, Mori T, et al. High‐dose cuta‐
neous exposure to mite allergen induces IgG‐mediated protection against anaphylaxis. 
Clinical and Experimental Allergy: Journal of the British Society for Allergy and Clinical 
Immunology. 2016;46:992–1003. DOI: 10.1111/cea.12722
[58] Freiberger SN, Zehnder M, Gafvelin G, Gronlund H, Kundig TM, Johansen P. IgG4 but 
no IgG1 antibody production after intralymphatic immunotherapy with recombinant 
MAT‐Feld1 in human. Allergy. 2016;71:1366–1370.DOI: 10.1111/all.12946
[59] Durham SR, Till SJ. Immunologic changes associated with allergen immunother‐
apy. Journal of Allergy and Clinical Immunology. 1998;102:157–164. DOI: 10.1016/
S0091‐6749(98)70079‐X
Allergen-Specific Immunotherapy Follow-Up by Measuring Allergen-Specific IgG as an Objective Parameter
http://dx.doi.org/10.5772/66711
399
[60] Ebner C. Immunological mechanisms operative in allergen‐specific immunotherapy. 
International Archives of Allergy and Immunology. 1999;119:1–5. DOI: 24168
[61] Ewan PW. New insight into immunological mechanisms of venom immunotherapy. 
Current Opinion in Allergy and Clinical Immunology. 2001;1:367–374. DOI: 10.1097/00
130832‐200108000‐00015
[62] Wachholz PA, Durham SR. Mechanisms of immunotherapy: IgG revisited. Current 
Opinion in Allergy and Clinical Immunology. 2004;4:313–318. DOI: 10.1097/01.all. 
0000136753.35948.c0
[63] van Neerven RJ, Arvidsson M, Ipsen H, Sparholt SH, Rak S, Wurtzen PA. A double‐blind, 
placebo‐controlled birch allergy vaccination study: inhibition of CD23‐mediated serum‐
immunoglobulin E‐facilitated allergen presentation. Clinical and Experimental Allergy: 
Journal of the British Society for Allergy and Clinical Immunology. 2004;34:420–428. 
DOI: 10.1111/j.1365‐2222.2004.01899.x
[64] Wang JY, Lei HY, Hsieh KH. The change of allergen‐specific IgG subclass antibod‐
ies during immunotherapy in mite‐sensitive asthmatic children. Asian Pacific Journal 
of Allergy and Immunology/Launched by the Allergy and Immunology Society of 
Thailand. 1992;10:11–18.
[65] Einarsson R, Dreborg S, Hammarstrom L, Lofkvist T, Smith CI, Svensson G. Monitoring 
of mite Dermatophagoides farinae allergen‐specific IgG and IgG subclass distribution in 
patients on immunotherapy. Allergy. 1992;47:76–82. DOI: 10.1111/j.1398‐9995.1992.
tb05092.x
[66] Pastorello EA, Incorvaia C, Gerosa A, Vassellatti D, Italia M, Pravettoni V. Allergen spe‐
cific IgG subclass antibody response in hyposensitization with Dermatophagoides pteron-
yssinus extract. New England and Regional Allergy Proceedings. 1987;8:417–421. DOI: 
10.2500/108854187778999630
[67] Silva DA, Gervasio AM, Sopelete MC, Arruda‐Chaves E, Arruda LK, Chapman MD, 
et al. A sensitive reverse ELISA for the measurement of specific IgE to Der p 2, a major 
Dermatophagoides pteronyssinus allergen. Annals of Allergy, Asthma & Immunology: 
Official Publication of the American College of Allergy, Asthma and Immunology. 
2001;86:545–50. DOI: 10.1016/S1081‐1206(10)62903‐1
[68] Taketomi EA, Silva DAO. Method for quantifying allergen‐especific human IgG sub‐
classes for the control and attendance of specific immunotherapy. European patent 
office EP 2232265. 2016.
[69] Miyazawa H, Inouye S, Sakaguchi M, Koizumi K. A reverse‐sandwich ELISA for 
IgG antibody to a pollen allergen. The Journal of Allergy and Clinical Immunology. 
1988;82:407–413. DOI: 10.1016/0091‐6749(88)900139
Immunotherapy - Myths, Reality, Ideas, Future400
[70] Miyazawa H, Bannai H, Yanase T, Morita C, Satoh S, Sugiyama J, et al. A reverse‐sandwich 
enzyme‐linked immunosorbent assay for verocytotoxin 1 and 2 antibodies in human 
and bovine sera. Clinical and Diagnostic Laboratory Immunology. 1999;6:701–704.
[71] Queirós MGJ, Silva DAO, Alves R, Chiba HF, Amaral VBS, Almeida KC, et al. Mite‐spe‐
cific immunotherapy using allergen and/or bacterial extracts in atopic patients in Brazil. 
Journal of Investigational Allergology and Clinical Immunology. 2008;18:84–92.
Allergen-Specific Immunotherapy Follow-Up by Measuring Allergen-Specific IgG as an Objective Parameter
http://dx.doi.org/10.5772/66711
401

